Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action

Aroda, Vanita R.; Ciaraldi, Theodore P.; Chang, Sang-Ah; Dahan, Michael H.; Chang, R. Jeffrey; Henry, Robert R.

doi:10.1016/j.fertnstert.2007.04.046

Cited by 57 publications

(41 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of multiple bands following electrophoresis under nonreducing conditions (Fig. 3) is in agreement with our previous work (2,4,19) and that of Waki et al (36).…”

Section: Subject Characteristicssupporting

confidence: 92%

Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans

Phillips¹,

Kung²,

Ciaraldi³

et al. 2009

American Journal of Physiology-Endocrinology and Metabolism

Self Cite

View full text Add to dashboard Cite

Adiponectin, an insulin-sensitizing factor secreted from adipose tissue, is decreased in individuals with type 2 diabetes (T2D) and increased in response to thiazolidinedione (TZD) therapy. Changes in its secretion and assembly into higher-order forms affect insulin sensitivity. To determine the relative potency of TZDs on intra-adipocyte multimerization and secretion of adiponectin, we assessed the impact of in vivo low-or high-dose rosiglitazone treatment alone or combined with metformin in subjects with T2D. T2D subjects received high-dose rosiglitazone (8 mg/day), high-dose metformin (2,000 mg/day), or low-dose combination rosiglitazone-metformin therapy (4 mg ϩ 1,000 mg/day) for 4 mo. All subjects were then switched to high-dose rosiglitazonemetformin combination therapy (8 mg ϩ 2,000 mg/day) for another 4 mo. Low-dose rosiglitazone increased serum adiponectin, whereas the high dose increased both adipocyte content and serum adiponectin levels. TZDs selectively increased the percentage of circulating adiponectin in the potent, high-molecular-weight (HMW) form. No TZD effects were evident on multimer distribution in the cell. Expression of the chaperone protein ERp44, which retains adiponectin within the cell, was decreased by TZD treatment. No changes occurred in Ero1-L␣ expression. Metformin had no effect on any of these measures. Increases in adiponectin correlated with improvements in insulin sensitivity. In vivo, TZDs have apparent dose-dependent effects on cellular and secreted adiponectin. TZD-mediated improvements in whole body insulin sensitivity are associated with increases in circulating but not cellular levels of the HMW adiponectin multimer. Finally, TZDs promote the selective secretion of HMW adiponectin, potentially, in part, through decreasing the expression of the adiponectin-retaining protein ERp44. thiazolidinedione; adipocyte; ERp44; Ero1-L␣; chaperone proteins AS THE PREVALENCE OF OBESITY CONTINUES to rise at an alarming rate, so do associated rates of obesity-related metabolic dysfunction; among these are coagulation abnormalities, dyslipidemia, hyperinsulinemia, glucose intolerance, and type 2 diabetes (13, 34). Although long recognized to play a role in fat metabolism, the endocrine role of adipose tissue is a relatively recent and important discovery, potentially providing a link between obesity and disorders of metabolism. Among the growing list of identified adipose endocrine products, adiponectin is uniquely related to changes in insulin sensitivity. Low levels are seen in obesity and insulin-resistant states and are predictive of type 2 diabetes (15), whereas high levels are associated with leanness and greater insulin sensitivity (28, 40) and reduced risk for development of type 2 diabetes (14).Although synthesized as a 32-kDa monomeric protein, adiponectin undergoes extensive posttranslational processing and assembly into low-molecular-weight (LMW) trimers, middlemolecular-weight (MMW) heximers, and high-molecularweight (HMW) complexes prior to secretion (38). In vitro, the HM...

show abstract

“…The presence of multiple bands following electrophoresis under nonreducing conditions (Fig. 3) is in agreement with our previous work (2,4,19) and that of Waki et al (36).…”

Section: Subject Characteristicssupporting

confidence: 92%

Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans

Phillips¹,

Kung²,

Ciaraldi³

et al. 2009

American Journal of Physiology-Endocrinology and Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent study also showed that adiponectin levels are related to the degree of glucose intolerance and IR (31). However, in the present study, adiponectin level was not associated with IR markers, except for fasting glucose (r = -0.35, P < 0.05).…”

Section: Discussioncontrasting

confidence: 82%

The Effects of Raw Red Onion Consumption on Serum Levels of Adiponectin, Leptin, and hs-CRP in Overweight/Obese Females with Polycystic Ovarian Syndrome: A Randomized Controlled-Clinical Trial

Saghafi-Asl

Ebrahimi-Mameghani

2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

show abstract

“…According to the effects of excess adiposity and IR on adiponectin levels, a marked decrease of adiponectin levels in women with PCOS can be assumed. This assumption has been confirmed by the findings of numerous studies (24,25). As mentioned above, both MetS and PCOS are related with low adiponectin levels and it is expected that women with concomitant PCOS and MetS would have lower adiponectin levels compared to women with PCOS only.…”

Section: Discussionsupporting

confidence: 62%

Prediction of metabolic syndrome in women with polycystic ovary syndrome

Ersan¹,

Arslan²,

Esmer³

et al. 2012

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Objective: To identify biochemical factors that serve as predictors for the metabolic syndrome (MetS) in patients with polycystic ovary syndrome (PCOS) and to investigate the value of adipocytokines in the prediction of metabolic syndrome. Material and Methods:A total of 91 pre-menopausal women with PCOS diagnosed according to the Rotterdam consensus criteria were recruited as study subjects. Waist circumference, blood pressure, body mass index (BMI), fasting glucose, serum lipids, insulin, FSH, LH, E 2 , total testosteron, homeostatic model assessment-insulin resistance (HOMA-IR), serum leptin and adiponectin levels were evaluated for all patients. Results:Of the 91 women with PCOS, 15 patients met the criteria for MetS. Body weight, BMI, waist circumference, systolic blood pressure, diastolic blood pressure, fasting glucose, total cholesterol, triglyceride, and VLDL concentrations were significantly higher and HDL was significantly lower in women with PCOS+MetS compared with those with PCOS only. However, the level of LDL, FSH, LH, E 2 and total testesterone was not significantly different between these two groups. Women with PCOS+MetS had significantly higher levels of leptin and HOMA-IR, and significantly lower levels of adiponectin compared to the women with PCOS only. In the multiple logistic regression model, the association between HOMA-IR and leptin, and MetS remained statistically significant (p=0.001 and 0.018), while the association between adiponectin and MetS was no longer statistically significant. Conclusion: Abstract ÖzetOriginal Investigation 178

show abstract

Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action

Abstract: Both circulating adiponectin levels and the portion present as the most active HMW form are reduced in PCOS, with differences related to the degree of glucose intolerance and insulin resistance.

Cited by 57 publications

References 45 publications

Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans

Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans

The Effects of Raw Red Onion Consumption on Serum Levels of Adiponectin, Leptin, and hs-CRP in Overweight/Obese Females with Polycystic Ovarian Syndrome: A Randomized Controlled-Clinical Trial

Prediction of metabolic syndrome in women with polycystic ovary syndrome

Contact Info

Product

Resources

About